CancerDrs

Pancreatic Cancer clinical trials in Rhode Island

9 actively recruiting pancreatic cancer trials at 2 sites across Rhode Island.

Data from ClinicalTrials.gov · last refreshed

Phase 2 Recruiting Network

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05040360
Sites in Rhode Island:
  • Smilow Cancer Hospital Care Center - Westerly — Westerly, Rhode Island
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in partici…

Sponsor: Genentech, Inc.
NCT ID: NCT05968326
Sites in Rhode Island:
  • Rhode Island Hospital — Providence, Rhode Island
  • Miriam Hospital — Providence, Rhode Island
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study for AZD4360 in Participants With Advanced Solid Tumours

The purpose of this study is to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD4360 in adult participants with locally advanced or metastatic solid tumours selected for expression of…

Sponsor: AstraZeneca
NCT ID: NCT06921928
Sites in Rhode Island:
  • Research Site — Providence, Rhode Island
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma

The purpose of this study is to determine if combination treatment with cemiplimab, motixafortide, gemcitabine, and nab-paclitaxel is effective in decreasing the size of the tumor(s), if it will prolong life in patients, and if it's safe. …

Sponsor: Gulam Manji
NCT ID: NCT04543071
Sites in Rhode Island:
  • Brown University — Providence, Rhode Island
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This study also aims to find the best dose. This study is seeking participants who have…

Sponsor: Pfizer
NCT ID: NCT06447662
Sites in Rhode Island:
  • Rhode Island Hospital — Providence, Rhode Island
  • Miriam Hospital — Providence, Rhode Island
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Rhode Island:
  • Providence Veterans Administration Hospital — Providence, Rhode Island
View on ClinicalTrials.gov →
Recruiting Network

Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers

The purpose of this study is to compare two approaches for monitoring pancreatic cysts as well as to identify associated biomarkers. The study doctors want to compare more frequent monitoring versus less frequent monitoring as well as iden…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04239573
Sites in Rhode Island:
  • Smilow Cancer Hospital Care Center - Westerly — Westerly, Rhode Island
View on ClinicalTrials.gov →
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Rhode Island:
  • Massive Bio SYNERGY-AI site — Providence, Rhode Island
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-06-15